Analyst Calls These 2 Drug Stocks a "Buy"

Both CRBP and NURO have been struggling on the charts

Dec 26, 2018 at 3:14 PM
facebook twitter linkedin


The shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) are trading up 5.9% at $5.57, after H.C. Wainwright initiated coverage with a "buy" rating and $24 price target -- a more than 356% premium to Monday's close. The analyst in coverage said positive data from lenabasum trials could drive upside in the shares.

Analysts are already bullish on CRBP stock, with 100% of those covering the security calling it a "buy." Plus, the average 12-month price target sits all the way up at $23.43.

Looking at the charts, Corbus Pharmaceuticals stock has been in a channel of lower highs and lows since its early October peak at $8.57. Last week, the shares broke below short-term support at their 120-day moving average, and remain down 21.6% year-to-date. Should the security resume its longer-term downtrend, a re-evaluation from the upbeat analyst bunch could create headwinds for CRBP.

crbp stock chart on dec 26

H.C. Wainwright also chimed in on Neurometrix Inc (NASDAQ:NURO), starting coverage with a "buy" rating and $5 price target -- territory the penny stock hasn't explored since April 2017. The brokerage firm said it sees "plenty of room for the stock to appreciate," and said a new generation of its Quell technology could help grow market share.

At last check, NURO stock is 13.5% higher at $0.77, but running into resistance near its 20-day moving average. While this trendline has led the security on its most recent leg lower, the 200-day moving average has helped usher the shares to a 58% year-to-date loss.

nuro stock chart on dec 26

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners